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Abstract Androgens play an important role in the regulation of
bone metabolism in animals and humans. The present study was
performed to investigate whether androgens would affect
osteoclast formation stimulated by parathyroid hormone (PTH)
in mouse bone cell cultures and its mechanism. Testosterone as
well as K-dihydrotestosterone (DHT) concentration-dependently
inhibited osteoclast formation induced by PTH-(1-34). 1038 M
ICI 182780, an estrogen receptor inhibitor, did not affect PTH-
induced osteoclast formation antagonized by 1038 M testoster-
one, although it completely antagonized the effects of 1038 M
17L-estradiol. Moreover, 3 WM 4-androsten-4-ol-3,17-dione, an
aromatase inhibitor, did not affect PTH-induced osteoclast
formation antagonized by testosterone. Hydroxyflutamide, an
androgen receptor antagonist, concentration-dependently antag-
onized the inhibitory effects of testosterone as well as DHT on
PTH-stimulated osteoclast formation. In conclusion, the present
study first demonstrated that testosterone inhibited osteoclast
formation stimulated by PTH through the androgen receptor, but
not through the production of intrinsic estrogen in mouse bone
cell cultures. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Androgens play an important role in the regulation of bone
metabolism in animals and humans [1^4]. Osteoporosis in
men is a serious health problem in an aging population [5],
and decreased androgen levels have been linked to lower bone
mineral density in men [6]. Moreover, there is a strong corre-
lation between hypogonadism in elderly men and spinal os-
teoporosis [5,6], and androgen treatment of osteoporotic men
and women is e¡ective in increasing bone mineral density [7].
Gonadal androgens including testosterone act directly on
osteoblasts, stimulating growth and di¡erentiation of osteo-
blastic cells in vitro by binding to an androgen receptor [8,9].
As for bone resorption, Mizuno et al. [10] reported the exis-
tence of androgen receptors in mouse osteoclast-like cells and
the recent study [11] revealed that androgens regulated bone-
resorbing activity of isolated chicken osteoclasts. Osteoclastic
bone resorption is accelerated by the development of new
osteoclasts as well as the activation of quiescent osteoclasts.
However, no reports have been available about whether an-
drogens would a¡ect osteoclast formation or not.
Parathyroid hormone (PTH) stimulates bone resorption by
accelerating osteoclast formation and bone-resorbing activity
of mature osteoclasts [12,13]. Our previous study [14] revealed
that estrogen blocked PTH-stimulated osteoclast formation by
selectively a¡ecting PTH-responsive cAMP pathway in mouse
bone cell cultures. Several studies [15^18] suggested that an-
drogens act on bone cells mainly through the conversion of
testosterone to estrogen. The present study was, therefore,
performed to investigate whether androgens such as testoster-
one and K-dihydrotestosterone (DHT), an active form of tes-
tosterone, would a¡ect osteoclast formation induced by PTH
in mouse bone cell cultures and to clarify its mechanism.
2. Materials and methods
2.1. Materials
ICR mice were obtained from Japan Clea Co. (Tokyo, Japan). 17L-
Estradiol (17L-E2), testosterone, DHT and 4-androsten-4-ol-3,17-di-
one were purchased from Sigma Chemical Co. (St. Louis, MO, USA),
human (h) PTH-(1-34) from Peptide Institute (Osaka, Japan), ICI
182780 was from Tocris (Ballwin, MO, USA). 1,25-Dihydroxyvitamin
D3 (1,25-(OH)2D3) and hydroxy£utamide were kindly provided by
Chugai Pharma Co. Ltd. (Shizuoka, Japan) and Nippon Kayaku
Co. Ltd. (Tokyo, Japan), respectively. All other chemicals used were
of analytical grade.
2.2. Mouse bone cell culture and osteoclast formation
Osteoclast formation from mouse unfractionated bone cells was
measured, as previously described [12]. Femora and tibiae of 10^15-
day-old ICR mice were aseptically removed. The bones from 10 mice
were dissected free of soft tissues and mechanically minced with a
scalpel blade in phenol red-free Eagle’s essential medium (MEM)
containing 5% charcoal-treated fetal calf serum (FCS). After removal
of bone fragments by sedimentation under normal gravity, unfraction-
ated bone cell suspensions were collected from the supernatant.
These unfractionated bone cells included tartrate-resistant acid phos-
phatase (TRAP)-positive multinucleated cells (MNCs), alkaline phos-
phatase-positive mononuclear cells (probably osteoblasts) and other
bone marrow cells. For cell spotting, the number of TRAP-positive
cells containing three or more nuclei was counted as TRAP-positive
MNCs in these bone cell suspensions. To examine the e¡ect of each
chemical on osteoclast formation using a population of preexistent
osteoclast-free bone cells, we spotted these mouse bone cells in 96-
well plates at 160 TRAP-positive MNCs/well (1U105 cells/well). Un-
fractionated bone cells were cultured in MEM containing 5% FCS at
37‡C in a humidi¢ed 10% CO2^90% air atmosphere for 5 days, by
which time preexistent osteoclasts (mature osteoclasts existing at the
beginning of culture) had degenerated and few TRAP-positive MNCs
were observed after 5 days of culture, as previously described in detail
[12]. Thus, we could test the e¡ects of osteotropic factors on the
sequential process leading to osteoclast formation by adding those
factors to the cultures after degeneration of preexistent osteoclasts.
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That is, this method allows us to analyze osteoclast formation in the
presence of osteoblasts. Each chemical was added to these osteoclast-
free bone cell cultures. After 7 days of culture, cells adherent to the
plates were washed with phosphate-bu¡ered saline, dried, and
promptly stained for TRAP. Cells were viewed under an inverted
phase-contrast microscope and the number of TRAP-positive
MNCs was counted. These newly formed TRAP-positive MNCs
had various characteristics of osteoclasts, including responsiveness
to calcitonin and bone-resorbing activity, as previously described [12].
2.3. Statistical analysis
Statistical analysis was performed by Student’s t test or Duncan’s
multiple range test. Results of ¢gures are representative of at least
three separate cell preparations. Similar results were obtained from
other cell preparations.
3. Results and discussion
We ¢rst examined whether androgens would a¡ect osteo-
clast formation stimulated by PTH and 1,25-(OH)2D3 in
mouse bone cell cultures. As shown in Fig. 1, 1038 M PTH-
(1-34) stimulated MNC formation and testosterone concentra-
tion-dependently inhibited MNC formation induced by PTH.
However, testosterone did not a¡ect MNC formation induced
by 1038 M 1,25-(OH)2D3. This is the ¢rst evidence that tes-
tosterone inhibits osteoclast formation. In our previous study
[14], estrogen inhibited osteoclast formation induced by PTH,
although it did not a¡ect osteoclast formation induced by
1,25-(OH)2D3 in mouse bone cell cultures. The e¡ects of tes-
tosterone in the present study are analogous to those of estro-
gen in our previous study. DHT has a greater a⁄nity for
androgen receptors and cannot be aromatized. Human bone
is capable of metabolizing testosterone to DHT [19]. We,
therefore, examined whether DHT would a¡ect osteoclast for-
mation stimulated by PTH in mouse bone cell cultures. As
shown in Fig. 1, DHT concentration-dependently inhibited
MNC formation stimulated by PTH and its potency seemed
to be somewhat stronger, compared to that of testosterone.
Several studies [15,16] revealed that bone mineral density of
the lumbar spine and hip was positively related to serum
concentration of estradiol in men, supporting the concept
that the actions of testosterone on the male skeleton may be
mediated in part by aromatization to estrogen [17]. Moreover,
in a recent case report of osteoporosis in a 28-year-old man
with a mutation of the aromatase gene, treatment with intra-
muscular testosterone produced no bene¢t but transdermal
estradiol resulted in skeletal maturation, a rapid increase in
lumbar spine bone density and closure of the epiphyses [18].
On the other hand, many studies have con¢rmed the presence
of androgen receptors in bone cells and the ability of these
cells to respond to androgens [20]. These ¢ndings have raised
the following possibilities: ¢rst, testosterone might inhibit os-
teoclast formation induced by PTH through the conversion to
estrogen by aromatase in bone cells. Second, testosterone
might inhibit osteoclast formation induced by PTH through
the androgen receptors in a manner independent of intrinsic
estrogen in bone cells. We, therefore, employed a speci¢c es-
trogen receptor antagonist, ICI 182780, and an aromatase
inhibitor, 4-androsten-4-ol-3,17-dione, to examine whether
testosterone would inhibit osteoclast formation induced by
PTH through estrogen receptor or aromatase in mouse bone
cell cultures. As shown in Fig. 2, 1038 M 17L-E2 signi¢cantly
inhibited PTH-induced MNC formation and 1038 M ICI
182780 completely antagonized the e¡ects of 17L-E2. How-
ever, 1038 M ICI 182780 did not a¡ect MNC formation an-
tagonized by 1038 M testosterone. These data indicated that
testosterone inhibited osteoclast formation induced by PTH
by the mechanism other than estrogen receptor. Moreover,
3 WM 4-androsten-4-ol-3,17-dione did not a¡ect PTH-induced
MNC formation antagonized by testosterone in mouse bone
cell cultures (Fig. 2), indicating that testosterone inhibited
osteoclast formation induced by PTH in a manner indepen-
Fig. 1. E¡ect of androgens on osteoclast formation stimulated by
PTH or 1,25-(OH)2D3 in mouse bone cell cultures. After degenera-
tion of preexistent osteoclasts, 1038 M hPTH-(1-34) (PTH) and
1038 M 1,25-(OH)2D3 were added with or without the indicated
concentrations of testosterone (T) or DHT, followed by 7 days of
culture. Then, the number of TRAP-positive MNCs was counted,
as described in Section 2. Data are expressed as the mean þ S.E.M.
of four determinations. *P6 0.01, compared to control. **P6 0.01,
compared to PTH-treated group.
Fig. 2. Role of estrogen receptor and aromatase in the e¡ects of tes-
tosterone on PTH-stimulated osteoclast formation. After degenera-
tion of preexistent osteoclasts, 1038 M hPTH-(1-34) (PTH), 1038 M
PTH and 1038 M 17L-E2, and 1038 M PTH and 1038 M testoster-
one (T) were added with or without 1038 M ICI 182780 (ICI) or
3 WM 4-androsten-4-ol-3,17-dione (AI), followed by 7 days of cul-
ture. Then, the number of TRAP-positive MNCs was counted, as
described in Section 2. Data are expressed as the mean þ S.E.M. of
four determinations. *P6 0.01, compared to control. **P6 0.01,
compared to PTH-treated group.
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dent of the conversion to estrogen by aromatase. The present
¢ndings indicated that testosterone inhibited osteoclast forma-
tion induced by PTH in a manner independent of the produc-
tion of intrinsic estrogen in bone cells.
We, next, examined whether testosterone would inhibit os-
teoclast formation through androgen receptor in mouse bone
cell cultures. We employed hydroxy£utamide, the androgen
receptor antagonist, to clarify this issue. As shown in Fig. 3,
hydroxy£utamide concentration-dependently antagonized the
inhibitory e¡ects of testosterone on PTH-induced MNC for-
mation in mouse bone cell cultures, although hydroxy£uta-
mide itself did not a¡ect MNC formation. Moreover, 1039
M DHT signi¢cantly inhibited MNC formation stimulated
by PTH and 1037 M hydroxy£utamide signi¢cantly antago-
nized the inhibitory e¡ects of DHT. These ¢ndings indicated
that testosterone inhibited osteoclast formation by an andro-
gen receptor-mediated mechanism in mouse bone cell cultures.
Androgen receptor exists on osteoclasts as well as on osteo-
blasts [8^10]. Mouse bone cell cultures employed in the
present study include osteoblasts, osteoclast precursors and
osteoclasts. We, therefore, could not clarify which cells are
responsible for the inhibitory e¡ects of testosterone on osteo-
clast formation in the present study. Further study is neces-
sary to clarify these issues.
In conclusion, the present study ¢rst demonstrated that
testosterone inhibited osteoclast formation induced by PTH
through the androgen receptor, but not through the produc-
tion of intrinsic estrogen in mouse bone cell cultures.
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Fig. 3. Role of androgen receptor in the e¡ects of testosterone on
PTH-stimulated osteoclast formation. After degeneration of preexis-
tent osteoclasts, 1038 M hPTH-(1-34) (PTH), 1038 M PTH and
1038 M testosterone (T), and 1038 M PTH and 1039 M DHT were
added with or without the indicated concentrations of hydroxy£uta-
mide (HF), followed by 7 days of culture. Then, the number of
TRAP-positive MNCs was counted, as described in Section 2. Data
are expressed as the mean þ S.E.M. of four determinations.
*P6 0.01, compared to control. **P6 0.01, compared to PTH-
treated group. ***P6 0.01, compared to PTH and T- or DHT-
treated group.
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